Pradžia › Židinė alopecija › Indianas
Židinė alopecija klinikiniai tyrimai Indianas
8 tyrimai dėl Židinė alopecija ieško dalyvių vietose Indianas.
Miestai Indianas
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
- Dawes Fretzin- Indianapolis /ID# 283498, Indianapolis
Renkami dalyviai3 fazė
Amžius nuo 6 iki 17 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07772492A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT06873945HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
- Dawes Fretzin Clinical Research Group, Indianapolis
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07049328A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-10 · NCT07733765A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- Indiana University Health University Hospital /ID# 259827, Indianapolis
Renkami dalyviai3 fazė
Amžius nuo 12 iki 63 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06012240A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Renkami dalyviai3 fazė
Amžius nuo 6 iki 14 · Visoms lytims · Atnaujinta 2026-04-28 · NCT07029828A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
- Options Research Group, West Lafayette
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 55 · Visoms lytims · Atnaujinta 2026-03-04 · NCT06826196Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- Ds Research - Indiana, Clarksville
- Dawes Fretzin Clinical Research Group Llc., Indianapolis
Renkami dalyviai3 fazė
Amžius nuo 12 iki 17 · Visoms lytims · Atnaujinta 2026-01-28 · NCT07133308Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.